Jun 26, 2026 08:02AM
Jun 26, 2026 08:00AM
May 15, 2026 04:15PM
May 12, 2026 08:09AM
May 12, 2026 08:00AM
Apr 16, 2026 08:04AM
Apr 16, 2026 08:00AM Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
Mar 30, 2026 04:50PM
Mar 3, 2026 08:02AM
Mar 3, 2026 08:00AM
Jan 5, 2026 08:03AM
Jan 5, 2026 08:00AM
Dec 2, 2025 08:05AM
Dec 2, 2025 08:00AM Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
Nov 20, 2025 08:00AM
Nov 20, 2025 08:00AM
Nov 14, 2025 04:15PM
Aug 13, 2025 04:15PM
Jul 31, 2025 08:00AM
Jul 31, 2025 08:00AM
Jul 16, 2025 08:00AM Ensysce Biosciences begins phase 3 trial for abuse-resistant opioid PF614
Jul 16, 2025 08:00AM
Jun 24, 2025 08:00AM
Jun 4, 2025 08:12AM
Jun 4, 2025 08:00AM
May 13, 2025 04:15PM
Apr 15, 2025 08:04AM
Apr 15, 2025 08:00AM Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study
Mar 10, 2025 04:15PM
Mar 3, 2025 09:43AM
Feb 5, 2025 08:05AM
Feb 5, 2025 08:00AM
Jan 22, 2025 08:01AM
Jan 22, 2025 08:00AM
Jan 8, 2025 08:03AM Ensysce Biosciences (ENSC) Issues Annual Shareholder Letter
Jan 8, 2025 08:00AM
Nov 26, 2024 08:00AM
Nov 12, 2024 04:15PM
Oct 2, 2024 08:08AM
Oct 2, 2024 08:00AM
Sep 24, 2024 08:00AM
Sep 19, 2024 07:03AM Ensysce Biosciences (ENSC) Submits Phase 3 Protocol to the FDA
Sep 19, 2024 07:00AM
Sep 13, 2024 08:00AM
Aug 29, 2024 08:04AM
Aug 29, 2024 08:00AM
Aug 27, 2024 02:32PM
Aug 27, 2024 02:30PM
Aug 27, 2024 08:10AM Ensysce Biosciences (ENSC) Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection
Aug 27, 2024 08:00AM

324,409 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All